Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Clinical Oncology

• Publication date

  2013-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/jco.2013.31.6_suppl.155PMID 28136752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting

  2017cites this paper
• Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen (review of TA255)

  2016cites this paper
• Novel agents for castration‐resistant prostate cancer: Early experience and beyond

  2016cites this paper
• Sequencing Treatment for Castration-Resistant Prostate Cancer

  2016cites this paper
• Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.

  2015cites this paper
• Cytotoxic chemotherapy in the contemporary management of metastatic castration‐resistant prostate cancer (mCRPC)

  2015cites this paper
• Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.

  2015cites this paper
• CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel

  2015cites this paper
• Taxanes and Novel Androgen Receptor Targeted Agents in the Management of Metastatic Castration-Resistant Prostate Cancer

  2015influential citation
• Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.

  2015cites this paper
• Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.

  2015cites this paper
• Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

  2014cites this paper
• Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics

  2014cites this paper
• Treatment sequencing in metastatic castrate-resistant prostate cancer

  2014cites this paper
• Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

  2014cites this paper
• Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer

  2014cites this paper
• Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

  2014cites this paper
• Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.

  2014cites this paper
• Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer.

  2014cites this paper
• Metastatic Castrate-resistant Prostate Cancer: When and How to Treat?

  2014cites this paper
• Cytotoxic Chemotherapy (Taxanes and Taxane Combinations)

  2014cites this paper
• The changing landscape in metastatic castration-resistant prostate cancer

  2013cites this paper
• Current clinical challenges in prostate cancer

  2013cites this paper
• Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies

  2013cites this paper